Recent debate about the value of high-dose chemotherapy has centered on single therapy approaches. This concise, authoritative book discusses the possible utility of two or more consecutive high-dose therapies. Also discussed are novel ways to circumvent drug resistance, pharmacology, techniques of cell collection, and pharmacoeconomics.Recent debate about the value of high-dose chemotherapy has centered on single therapy approaches. This concise, authoritative book discusses the possible utility of two or more consecutive high-dose therapies. Also discussed are novel ways to circumvent drug resistance, pharmacology, techniques of cell collection, and pharmacoeconomics.M.S. Aapro and D. Maraninchi: High Dose, Low Dose, No Dose: The Rights and Wrongs of Medical Oncology; G. Martinelli, F. Peccatori and M. Gianni: Haematological Support: Progenitor Cell Collection and Processing; G. Vassal and O. Hartmann: Pharmacotoxicology of High-Dose Thiotepa; G. Vassal and O. Hartmann: Pharmacotoxicology of High-Dose VP-16; A.M. Stoppa, R. Bouabdallah, N. Vey et al.: Intensive Sequential Chemotherapy for Untreated Poor-Risk Non-Hodgkin's Lymphoma; J.L. Klein and W.P. Peters: High-Dose Chemotherapy with Autologous Haematopoietic Progenitor Cell Transplantation for Adenocarcinoma of the Breast; R.C.F. Leonard: Multiple Alkylating Agent Chemotherapy for Solid Cancers; M.S. Aapro and F. Nol?: The Health Economics of High-Dose ChemotherapyRecent debate about the value of high-dose chemotherapy has centered on single therapy approaches. This concise, authoritative book discusses the possible utility of two or more consecutive high-dose therapies. Also discussed are novel ways to circumvent drug resistance, pharmacology, techniques of cell collection, and pharmacoeconomics.An unusually short, authoritative, timely update of the field is presented.Springer Book ArchivesDE